Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14314439 | 0.92 | L3MBTL1 (0.58) | L3MBTL1TDP1KDM4ELMNARAB9A | |
| SCHEMBL27933805 | 0.84 | L3MBTL1 (0.57) | L3MBTL1TDP1KDM4ERAB9AKMT2A | |
| SCHEMBL5107176 | 0.83 | HPGD (0.56) | L3MBTL1TDP1LMNARAB9AKMT2A | |
| SCHEMBL13332620 | 0.83 | KDM4E (0.55) | L3MBTL1TDP1KDM4ELMNARAB9A | |
| SCHEMBL11585022 | 0.81 | ALDH1A1 (0.59) | L3MBTL1TDP1KDM4ELMNARAB9A | |
| SCHEMBL1264964 | 0.81 | LMNA (0.64) | L3MBTL1TDP1KDM4ELMNARAB9A | |
| SCHEMBL11196941 | 0.80 | KMT2A (0.59) | L3MBTL1TDP1LMNARAB9AKMT2A | |
| SCHEMBL28938376 | 0.79 | LMNA (0.62) | L3MBTL1TDP1KDM4ELMNARAB9A | |
| SCHEMBL7925431 | 0.79 | L3MBTL1 (0.54) | L3MBTL1TDP1KDM4ELMNARAB9A | |
| SCHEMBL29473477 | 0.79 | LMNA (0.62) | L3MBTL1TDP1KDM4ELMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670744-B1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LTD (IN) | 2015-05-27 | — | — | EP | disclosed |
| EP-2670744-B1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LTD (IN) | 2015-05-27 | — | — | EP | disclosed |
| EP-2670744-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | Lupin Limited (IN) | 2013-12-11 | — | — | EP | disclosed |
| US-20130310419-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LIMITED (IN) | 2013-11-21 | — | — | US | disclosed |
| WO-2012104782-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LIMITED (IN) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310419-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | CHRNA7, CHRNE, CHRNA5 | L3MBTL1 4708/4885TDP1 1728/4885KDM4E 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.